MVX-220 / MavriX Bio - LARVOL DELTA

ASCEND-AS: A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome (clinicaltrials.gov) - P1/2 | N=12 | Active, not recruiting | Sponsor: MavriX Bio, LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Gene Therapies • UBE3A

ASCEND-AS: A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: MavriX Bio, LLC

New P1/2 trial • Gene Therapies • UBE3A

ASCEND-AS: A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: MavriX Bio, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Gene Therapies • UBE3A

ASCEND-AS: A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: MavriX Bio, LLC | Active, not recruiting ➔ Recruiting

Enrollment open • Gene Therapies • UBE3A